Stock Scorecard
Stock Summary for uniQure N.V. (QURE) - $23.93 as of 12/19/2025 3:34:38 PM EST
Total Score
9 out of 30
Safety Score
44 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for QURE
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for QURE
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for QURE
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for QURE
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for QURE (44 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for QURE
Financial Details for QURE
Company Overview |
|
|---|---|
| Ticker | QURE |
| Company Name | uniQure N.V. |
| Country | USA |
| Description | uniQure NV is a pioneering gene therapy company based in Amsterdam, Netherlands, focused on delivering innovative treatments for genetic disorders and severe diseases. Leveraging its proprietary AAV-based gene therapy platform, uniQure is addressing significant unmet medical needs in critical areas, including hemophilia and neurodegenerative disorders. The company boasts a robust pipeline of promising product candidates and is committed to enhancing patient care through the advancement of breakthrough genetic therapies, positioning itself as a leader in the dynamic gene therapy market. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/2/2026 |
Stock Price History |
|
| Last Day Price | 23.93 |
| Price 4 Years Ago | 20.74 |
| Last Day Price Updated | 12/19/2025 3:34:38 PM EST |
| Last Day Volume | 3,112,230 |
| Average Daily Volume | 3,082,625 |
| 52-Week High | 71.50 |
| 52-Week Low | 7.76 |
| Last Price to 52 Week Low | 208.38% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 56.90 |
| Sector PE | 53.39 |
| 5-Year Average PE | -6.19 |
| Free Cash Flow Ratio | 2.50 |
| Industry Free Cash Flow Ratio | 22.58 |
| Sector Free Cash Flow Ratio | 33.77 |
| Current Ratio Most Recent Quarter | 7.12 |
| Total Cash Per Share | 9.58 |
| Book Value Per Share Most Recent Quarter | 3.68 |
| Price to Book Ratio | 6.52 |
| Industry Price to Book Ratio | 52.55 |
| Sector Price to Book Ratio | 49.15 |
| Price to Sales Ratio Twelve Trailing Months | 94.88 |
| Industry Price to Sales Ratio Twelve Trailing Months | 18.91 |
| Sector Price to Sales Ratio Twelve Trailing Months | 14.97 |
| Analyst Buy Ratings | 9 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 62,292,000 |
| Market Capitalization | 1,490,647,560 |
| Institutional Ownership | 91.67% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -18.20% |
| Annual Earnings Growth | 22.34% |
| Reported EPS 12 Trailing Months | -4.40 |
| Reported EPS Past Year | -2.80 |
| Reported EPS Prior Year | -4.87 |
| Net Income Twelve Trailing Months | -235,146,000 |
| Net Income Past Year | -239,556,000 |
| Net Income Prior Year | -308,478,000 |
| Quarterly Revenue Growth YOY | 61.80% |
| 5-Year Revenue Growth | 30.08% |
| Operating Margin Twelve Trailing Months | -1,330.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 597,056,000 |
| Total Cash Past Year | 158,930,000 |
| Total Cash Prior Year | 241,360,000 |
| Net Cash Position Most Recent Quarter | 545,176,000 |
| Net Cash Position Past Year | 107,606,000 |
| Long Term Debt Past Year | 51,324,000 |
| Long Term Debt Prior Year | 101,749,000 |
| Total Debt Most Recent Quarter | 51,880,000 |
| Equity to Debt Ratio Past Year | -0.15 |
| Equity to Debt Ratio Most Recent Quarter | 0.82 |
| Total Stockholder Equity Past Year | -6,752,000 |
| Total Stockholder Equity Prior Year | 207,670,000 |
| Total Stockholder Equity Most Recent Quarter | 228,746,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -153,751,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.47 |
| Free Cash Flow Past Year | -186,096,000 |
| Free Cash Flow Prior Year | -153,083,000 |
Options |
|
| Put/Call Ratio | 0.30 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -3.76 |
| MACD Signal | -4.53 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.59 |
| RSI | 40.88 |
| 50-Day SMA | 20.23 |
| 150-Day SMA | 13.17 |
| 200-Day SMA | 14.73 |
System |
|
| Modified | 12/20/2025 7:46:02 AM EST |